84057-84-1 | Lamotrigine

Chemical type

• Antiseizure medication (ASM)

^[1,2]

• Phenyltriazine derivative

^[2]

Key properties

• Enters saliva by passive diffusion
• Reflects free unbound fraction in plasma
• Lower salivary and plasma concentrations associated with seizure freedom
• No significant association with adverse events
• Strong correlation between saliva and plasma levels (R² = 0.70)

^[1]

• Mechanism of action: blocks voltage-gated sodium channels (VGSCs), enhancing both fast and slow inactivation
• Low teratogenicity
• May have a dose-dependent dual action on sodium channels, which could explain its unique efficacy profile in IGE

^[2]

• Treatment of epilepsy to achieve seizure freedom
• Monotherapy or add-on therapy in polytherapy regimens
• Therapeutic drug monitoring (TDM) for efficacy and dosage adjustment

^[1]

• Treatment of Idiopathic Generalized Epilepsy (IGE)
• Most effective at moderate doses (201-400 mg/day); higher doses (>400 mg/day) were not associated with better seizure control and showed decreased efficacy

^[2]

Classification by use

• Antiepileptic drugs
• Chemicals used in neurological disorder management

^[1]

• Chemicals used as pharmaceuticals (anticonvulsants)
• Alternative to valproate, especially for females of childbearing age

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?, Epilepsy & Behavior, Volume 171, October 2025, 110595
2. [Cite:2] Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy, Epilepsy & Behavior, Volume 177, April 2026, 110940